---
title: "Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006 | Sutter Health"
description: "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma"
url: "https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) /
4.  Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006

# Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006

**Status:** Open to Enrollment

[Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#enroll)

#### Study details

View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05346835).

#### Locations

-   Berkeley
-   Sacramento

#### Clinical trial FAQs

Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs).

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma

![Oleg I Krijanovski, M.D., Ph.D.](https://dyn.mktgcdn.com/p/oWPJWgCboUxqZApvrWha8T3bs6ZyRlMgoWXo_AiO4GI/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100)

Oleg I Krijanovski, M.D., Ph.D.

Principal investigator

[View profile](https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130)

![Elias Nicolas Kiwan, M.D.](https://dyn.mktgcdn.com/p/Ln5qmOw8juR1El0mtRJKrtbQHNcNqStCJ_aGFx9n45o/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100)

Elias Nicolas Kiwan, M.D.

Principal investigator

[View profile](https://www.sutterhealth.org/research/investigators/elias-nicolas-kiwan-md-2050562955)

## Email us to enroll

-   [Email Berkeley](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Multiple%20Myeloma%20Expanded%20Access%20to%20Ciltacabtagene%20Autoleucel%20\(Cilta-Cel\)%2068284528MMY4006%20in%20Berkeley&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.)
-   [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Multiple%20Myeloma%20Expanded%20Access%20to%20Ciltacabtagene%20Autoleucel%20\(Cilta-Cel\)%2068284528MMY4006%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.)

## Related clinical trials

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

-   Clinical trial
    
    ### [Interventional Myeloma EQUATE EAA181](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964)
    
    Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937)
    
    Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
    
    **Status:** Coming Soon
    
-   Clinical trial
    
    ### [Adjuvant Large B-Cell Lymphoma Alpha3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994)
    
    A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Cancer Young Female Adults Ovarian Damage Prevention ALTE2131](https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841)
    
    Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX](https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412)
    
    A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
    
    **Status:** Open to Enrollment
    

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006"}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#medicalwebpage","name":"Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006","description":"Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma","url":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#breadcrumblist"},"mentions":[{"@type":"Person","name":"Oleg I Krijanovski, M.D., Ph.D.","url":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}},{"@type":"Person","name":"Elias Nicolas Kiwan, M.D.","url":"https://www.sutterhealth.org/research/investigators/elias-nicolas-kiwan-md-2050562955","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446#medicaltrial","name":"Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006","alternateName":"Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma","url":"https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446","description":"Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma","identifier":"NCT05346835","code":{"@type":"MedicalCode","codeValue":"NCT05346835","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT05346835","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Hematologic Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Berkeley"},{"@type":"AdministrativeArea","name":"Sacramento"}]}
```
